About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

The 5 Most Interesting Analyst Questions From Moderna’s Q2 Earnings Call

MRNA Cover Image

Moderna’s second quarter results were met with a negative market reaction, as investors focused on both a sharp decline in year-over-year sales and ongoing operational challenges. Management attributed quarterly performance primarily to lower COVID vaccine demand and highlighted that U.S. sales performed above internal expectations due to a stronger spring booster campaign. CEO Stéphane Bancel pointed to significant cost-cutting efforts, including a 35% reduction in combined cost of sales and SG&A, and noted, “We remain highly focused on financial discipline.” The company also announced a 10% workforce reduction to further align its cost structure with current demand.

Is now the time to buy MRNA? Find out in our full research report (it’s free).

Moderna (MRNA) Q2 CY2025 Highlights:

  • Revenue: $142 million vs analyst estimates of $128.3 million (41.1% year-on-year decline, 10.7% beat)
  • Adjusted EPS: -$2.13 vs analyst estimates of -$3.00 (29% beat)
  • Adjusted EBITDA: -$850 million vs analyst estimates of -$1.21 billion
  • The company dropped its revenue guidance for the full year to $1.85 billion at the midpoint from $2 billion, a 7.5% decrease
  • Operating Margin: -639%, down from -566% in the same quarter last year
  • Market Capitalization: $9.98 billion

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Moderna’s Q2 Earnings Call

  • Salveen Jaswal Richter (Goldman Sachs) asked about the addition of secondary endpoints in the CMV vaccine trial; President Stephen Hoge explained this was to capture more data relevant to broader patient populations and that the final analysis will occur this fall.
  • Eliana Rachel Merle (UBS) inquired about U.S. COVID vaccine pricing; CFO James Mock declined to give specifics but said pricing and contracting are complete and factored into the current revenue range.
  • Michael Jonathan Yee (Jefferies) sought clarity on what would constitute a positive CMV readout and the influence of regulatory changes; Hoge emphasized the study was powered for over 49% vaccine efficacy and that regulator dialogues remain constructive.
  • Courtney Breen (Bernstein) questioned the focus of headcount reductions and potential areas of hiring; CEO Stéphane Bancel and Mock described cuts across manufacturing, R&D, and G&A, while highlighting ongoing hiring for launches and key capabilities.
  • Luca Issi (RBC) probed business development strategy and partnering in China; Bancel stated Moderna remains open to partnerships for non-mRNA assets and is prioritizing financial discipline over advancing all internal candidates.

Catalysts in Upcoming Quarters

Looking ahead, our team will closely watch (1) the pace of regulatory approvals and launches for the seasonal flu vaccine and the flu-COVID combination candidate, (2) the readout of Phase III efficacy data for the CMV vaccine and progress in oncology studies, and (3) the company’s execution on additional cost-cutting measures and ability to sustain operational efficiencies. Updates on product uptake in key international markets and further headway in pipeline diversification will also be important markers of success.

Moderna currently trades at $25.79, down from $29.56 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.